I agree it would be nice to have more publicity, and that will happen soon with publication, ESMO, and other means. Dr J will play by the rules and that's a good thing.
I think our bargaining power will come from the data, studies, improved clinical outcomes, mechanism of action, patents, potential for multiple indications including TnBC, other cancer indications, fibrosis, Alzheimer's, and HIV to name a few. Not the share price.
The share price is being manipulated. This could be by day traders, hedge funds, and the like who may or may not be also acting on behalf of a client(s) who has a vested interest in denying stock-market based sources of funding when they are potentially looking at providing the funding themselves via a licensing deal, partnership, buyout etc.
Why would you want a small biotech to get funding to go it alone when you can protect your own products and market share, and, at the same time, participate in the party of the small biotech you are interested in?
That's why the vast majority of successful biotech startups are licensed or bought out. I believe our miracle molecule will be like those others with this exception: We have more value because our miracle molecule LL can support a platform of indications.
Hang in there all us longs. We have been waiting a long time, but it will be work the wait
I think our bargaining power will come from the data, studies, improved clinical outcomes, mechanism of action, patents, potential for multiple indications including TnBC, other cancer indications, fibrosis, Alzheimer's, and HIV to name a few. Not the share price.
The share price is being manipulated. This could be by day traders, hedge funds, and the like who may or may not be also acting on behalf of a client(s) who has a vested interest in denying stock-market based sources of funding when they are potentially looking at providing the funding themselves via a licensing deal, partnership, buyout etc.
Why would you want a small biotech to get funding to go it alone when you can protect your own products and market share, and, at the same time, participate in the party of the small biotech you are interested in?
That's why the vast majority of successful biotech startups are licensed or bought out. I believe our miracle molecule will be like those others with this exception: We have more value because our miracle molecule LL can support a platform of indications.
Hang in there all us longs. We have been waiting a long time, but it will be work the wait
10
